CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Open Calls for Patient and Clinician Input

Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the Drug Reimbursement Review process.

At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.

Saxenda (liraglutide)

Therapeutic Area: Chronic weight management in adults

Call For Patient Input: November 26, 2020

Patient Input Closed: January 22, 2021

Ledaga (chlormethine hydrochloride)

Therapeutic Area: T-cell lymphoma

Call For Patient Input: November 23, 2020

Patient Input Closed: January 22, 2021

TBC (brexucabtagene autoleucel)

Therapeutic Area: Mantle cell lymphoma

Call For Patient Input: November 20, 2020

Patient Input Closed: January 22, 2021

TBC (idecabtagene vicleucel )

Therapeutic Area: Multiple myeloma

Call For Patient Input: November 19, 2020

Patient Input Closed: January 15, 2021

Braftovi and Mektovi (encorafenib and binimetinib)

Therapeutic Area: Advanced Melanoma

Call For Patient Input: November 17, 2020

Patient Input Closed: January 15, 2021

Braftovi (encorafenib)

Therapeutic Area: Metastatic colorectal cancer

Call For Patient Input: November 17, 2020

Patient Input Closed: January 15, 2021

Kineret (anakinra)

Therapeutic Area: Still's disease

Call For Patient Input: November 16, 2020

Patient Input Closed: January 15, 2021

Imfinzi (durvalumab)

Therapeutic Area: Extensive-stage small cell lung cancer

Call For Patient Input: November 3, 2020

Patient Input Closed: December 24, 2020

Keytruda (pembrolizumab )

Therapeutic Area: Colorectal cancer

Call For Patient Input: November 2, 2020

Patient Input Closed: December 24, 2020

Rybelsus (semaglutide)

Therapeutic Area: diabetes mellitus, type 2

Call For Patient Input: October 29, 2020

Patient Input Closed: December 17, 2020

Dupixent (dupilumab)

Therapeutic Area: Asthma

Call For Patient Input: October 29, 2020

Patient Input Closed: December 17, 2020

Reblozyl (luspatercept)

Therapeutic Area: beta-thalassemia associated anemia

Call For Patient Input: October 29, 2020

Patient Input Closed: December 17, 2020

Unituxin (dinutuximab)

Therapeutic Area: Neuroblastoma (pediatric)

Call For Patient Input: October 22, 2020

Patient Input Closed: December 10, 2020

TBC (risdiplam)

Therapeutic Area: Spinal muscular atrophy

Call For Patient Input: October 22, 2020

Patient Input Closed: December 10, 2020

Vitrakvi (larotrectinib)

Therapeutic Area: Solid tumours with NTRK gene fusion

Call For Patient Input: October 16, 2020

Patient Input Closed: December 4, 2020

Inrebic (fedratinib)

Therapeutic Area: Myelofibrosis

Call For Patient Input: October 7, 2020

Patient Input Closed: November 26, 2020

Jorveza (budesonide)

Therapeutic Area: Maintenance of Eosinophilic esophagitis in adults

Call For Patient Input: October 7, 2020

Patient Input Closed: November 26, 2020